KLRS logo

KLRS
Kalaris Therapeutics

124
Mkt Cap
$132.07M
Volume
63,403.00
52W High
$11.88
52W Low
$2.14
PE Ratio
-1.50
KLRS Fundamentals
Price
$6.30
Prev Close
$6.07
Open
$5.86
50D MA
$8.38
Beta
0.87
Avg. Volume
59,733.57
EPS (Annual)
-$2.85
P/B
1.83
Rev/Employee
$0.00
$12.33
Loading...
Loading...
News
all
press releases
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has earned an average rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. One investment...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 Shares
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of Kalaris Therapeutics stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $6.72, for a total transaction of $12,868.80. The transaction was disclosed in a legal...
MarketBeat·19d ago
News Placeholder
Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of the firm's stock in a transaction dated Friday, March 20th. The shares were sold at an average price of...
MarketBeat·20d ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·29d ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the company, Marketbeat.com...
MarketBeat·1mo ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold
Wall Street Zen raised Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Srinivas Akkaraju Buys 479,847 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of Kalaris Therapeutics stock in a transaction dated Thursday, December 18th. The stock...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction dated Thursday, December 18th. The shares were purchased at...
MarketBeat·2mo ago
News Placeholder
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 867,767 shares, an...
MarketBeat·2mo ago
<
1
2
...
>

Latest KLRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.